Lineage Cell Therapeutics (LCTX) 10-Q2021 Q1 Quarterly report

Filed: 13 May 21, 4:21pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: anesthesiologist, antigen, Biden, bio, Britain, CA, CAA, Canada, Center, Cohort, constitutionality, cooperation, Department, diverge, evidence, functionally, GA, gave, Great, handle, Immunomic, injunction, ITI, lowest, marketplace, nationwide, Northern, nurse, open, overturning, owner, presidential, reconsider, reexamining, restarted, risky, robust, territory, theft, tie, unnecessary, usability, waiver, withdrew

Removed: Advantage, affiliate, allotted, Amsterdam, arbitration, arrange, beneficiary, billing, billion, biosimilar, Blueprint, bookkeeping, calculation, calling, certiorari, charged, charity, circumvent, codified, collection, combination, commercialized, compensated, concurrently, conference, Conformit, consolidating, culturing, cumulative, de, deductible, define, depended, derecognition, derecognized, designated, devoted, disclosing, discounted, discretion, Disposal, documented, electorate, estimation, expiry, extension, feedback, forced, forgivable, formally, forum, fractional, fundamental, headcount, HHS, holder, HyStem, imaging, inaction, incentivize, inconsistent, informally, internally, invoice, invoiced, launch, leave, list, London, margin, marketability, markup, met, morale, multiplying, negotiating, Nordisk, Novo, Obama, occurring, oral, participant, penetration, percentage, poor, proportionate, proposal, prorated, ratably, ratio, refer, relocated, relocation, responding, resultant, retired, retrospective, scaffold, separation, sequester, settle, settled, software, spent, standalone, step, structural, structure, subjected, subset, successor, suggested, suit, superseded, technique, tenant, thirty, unchanged, unexercised, unit, video, view, voted

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated LCTX transcripts

LCTX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Lineage Cell Therapeutics, Inc. (the “Company”) for the quarter ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Brian M. Culley, Chief Executive Officer and Interim Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 13, 2021

/s/ Brian M. Culley
Brian M. Culley
Chief Executive Officer (Principal Executive Officer and Principal Financial Officer)